Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Focus Pharmaceuticals Ltd, Capital House, 1st Floor, 85 King William Street, London EC4N 7BL, United Kingdom
Ofcram PR 200mg Prolonged Release Capsules, Hard.
| Pharmaceutical Form |
|---|
|
Prolonged release capsules, hard. Appearance: Hard gelatin capsules consisting of a red cap and an orange body. Dimension 7,66 mm x 23,1 mm. The capsule contains yellow coloured slow release pellets. |
Each modified release capsule contains dipyridamole 200 mg.
Excipient(s) with known effect:
Sucrose: 4.56mg (2%w/w)
Sodium benzoate: 0.02mg (Up-to 1%w/v)
Sodium: 0.0032mg
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Dipyridamole |
Dipyridamole is an antithrombotic agent with antiplatelet activity. Dipyridamole has an antithrombotic action based on its ability to modify various aspects of platelet function, such as platelet aggregation, adhesion and survival, which are factors associated with the initiation of thrombus formation. |
| List of Excipients |
|---|
|
Tartaric acid pellets [Tartaric acid, Sucrose and Povidone] |
HDPE bottle with polypropylene child resistant closure, containing a desiccant in a pillow pouch.
Packs contain 60 capsules.
Focus Pharmaceuticals Ltd, Capital House, 1st Floor, 85 King William Street, London EC4N 7BL, United Kingdom
PL 20046/ 0270
18/10/2013
| Drug | Countries | |
|---|---|---|
| OFCRAM | United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
